Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Urelumab - Bristol-Myers Squibb

Drug Profile

Urelumab - Bristol-Myers Squibb

Alternative Names: Anti-4-1BB monoclonal antibody; Anti-CD137 monoclonal antibody - Medarex/Bristol-Myers Squibb; BMS-663513; BMS-66513; ONO-4481

Latest Information Update: 09 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex
  • Developer Bristol-Myers Squibb; National Cancer Institute (USA); Ono Pharmaceutical; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Chicago
  • Class Antineoplastics; Disulfides; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma; Solid tumours
  • Phase I Glioblastoma; Multiple myeloma
  • No development reported Colorectal cancer; Head and neck cancer; Malignant melanoma
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 26 Jul 2019 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV) before July 2019 (Ono Pharmaceutical pipeline, July 2019)
  • 10 Jun 2019 Interim safety and efficacy data from a phase I trial in Glioblastoma were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 29 Mar 2019 Bristol-Myers Squibb completes a phase I/II trial in Solid tumours and Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in Germany, France, USA and Spain (IV) (NCT02253992) (EudraCT2014-002241-22)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top